| scholarly article | Q13442814 |
| P50 | author | Stuart J. Gallagher | Q51847434 |
| P2093 | author name string | Peter Hersey | |
| P2860 | cites work | Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? | Q33205393 | ||
| Viral oncolysis | Q34124473 | ||
| ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 | ||
| Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. | Q34291195 | ||
| GM-CSF-secreting melanoma vaccines | Q35146599 | ||
| BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy | Q36175312 | ||
| Host immunity contributes to the anti-melanoma activity of BRAF inhibitors | Q36638192 | ||
| The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon | Q37561072 | ||
| Local and intralesional therapy of in-transit melanoma metastases | Q37920837 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma | Q38049494 | ||
| Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. | Q38453432 | ||
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. | Q39212469 | ||
| The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition | Q39254036 | ||
| Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells | Q40005154 | ||
| Intralesional BCG in the treatment of metastatic malignant melanoma | Q43420478 | ||
| Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter | Q44837123 | ||
| Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse | Q45223474 | ||
| Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma | Q47573472 | ||
| Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. | Q53168966 | ||
| P433 | issue | 4 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 320-326 | |
| P577 | publication date | 2013-12-03 | |
| P1433 | published in | Journal of Surgical Oncology | Q1919535 |
| P1476 | title | Intralesional immunotherapy for melanoma | |
| P478 | volume | 109 |
| Q52597538 | Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial. |
| Q37641458 | Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo |
| Q47791082 | Art, Science, and Personalized Cancer Care Through Regional Therapeutics |
| Q26752277 | Cancer immunotherapy: the beginning of the end of cancer? |
| Q36142487 | Designing Herpes Viruses as Oncolytics |
| Q28069615 | Developments in Intralesional Therapy for Metastatic Melanoma |
| Q37565521 | Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling |
| Q33923950 | Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses |
| Q42725119 | Immunovirotherapy for glioblastoma. |
| Q38742761 | Intralesional immunotherapy as a strategy to treat melanoma |
| Q38266193 | Intralesional therapy for metastatic melanoma |
| Q38518518 | Intratumoral immunotherapy for melanoma |
| Q55217220 | Melanoma treatment in review. |
| Q36583731 | Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. |
| Q34429032 | Non-viral vectors for gene-based therapy |
| Q38842126 | Oncolytic virotherapy for urological cancers |
| Q58317803 | Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease |
| Q26752803 | Production and clinical development of nanoparticles for gene delivery |
| Q91982102 | Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses |
| Q38352887 | Radiotherapy for cutaneous melanoma: current and future applications |
| Q41086684 | Talimogene Laherparepvec: First Global Approval |
| Q38534285 | Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma |
| Q56894524 | Talimogene laherparepvec: overview, combination therapy and current practices |
| Q35606611 | The Current State of Vaccine Development for Ocular HSV-1 Infection |
| Q38848885 | The oncolytic virus ΔPK has multimodal anti-tumor activity. |
| Q38781281 | The safety of talimogene laherparepvec for the treatment of advanced melanoma. |
| Q38250316 | Treating advanced melanoma: current insights and opportunities. |
| Q38817112 | ΔPK oncolytic activity includes modulation of the tumour cell milieu. |
Search more.